This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

10.3% of XBI Holdings Seeing Recent Insider Buys

Stock quotes in this article: MACK

A look at the weighted underlying holdings of the SPDR S&P Biotech ETF (XBI) shows an impressive 10.3% of holdings on a weighted basis have experienced insider buying within the past six months.

START SLIDESHOW:
10 ETFs With Stocks That Insiders Are Buying »

Merrimack Pharmaceuticals Inc. (MACK), which makes up 1.19% of the SPDR S&P Biotech ETF (XBI), has seen 6 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $13,397,309 worth of MACK, making it the #51 largest holding. The table below details the recent insider buying activity observed at MACK:

MACK — last trade: $7.04 — Recent Insider Buys:

Purchased Insider Title Shares Price/Share Value
05/05/2014 Michael E. Porter Director 15,000 $6.41 $96,150.00
05/05/2014 Gary L. Crocker Director 10,000 $6.69 $66,900.00
05/05/2014 Robert J. Mulroy President and CEO 5,000 $6.31 $31,550.00
05/06/2014 Gary L. Crocker Director 17,500 $6.89 $120,575.00
05/05/2014 Michael E. Porter Director 5,000 $6.12 $30,600.00
05/07/2014 Gary L. Crocker Director 4,400 $6.77 $29,788.00
05/07/2014 Sarah E. Nash Director 15,000 $6.79 $101,850.00
05/08/2014 Michael E. Porter Director 10,000 $6.59 $65,900.00
05/13/2014 Anthony J. Sinskey Director 5,000 $6.74 $33,700.00
05/16/2014 Michael E. Porter Director 15,000 $6.49 $97,400.00
05/19/2014 Gary L. Crocker Director 9,400 $6.68 $62,802.00
05/19/2014 James H. Quigley Director 5,000 $6.58 $32,900.00
05/20/2014 Gary L. Crocker Director 4,000 $6.69 $26,760.00
06/23/2014 Michael E. Porter Director 32,390 $6.84 $221,547.60
06/23/2014 Gary L. Crocker Director 36,000 $6.84 $246,240.00

And Synergy Pharmaceuticals Inc (SGYP), the #58 largest holding among components of the SPDR S&P Biotech ETF (XBI), shows 4 directors and officers as recently filing Form 4's indicating purchases. The ETF holds $12,889,101 worth of SGYP, which represents approximately 1.14% of the ETF's total assets at last check. The recent insider buying activity observed at SGYP is detailed in the table below:

SGYP — last trade: $3.58 — Recent Insider Buys:

Purchased Insider Title Shares Price/Share Value
05/23/2014 Bernard Denoyer Senior Vice President, Finance 2,500 $3.89 $9,725.00
05/23/2014 Kunwar Shailubhai Chief Scientific Officer 3,000 $3.89 $11,670.00
05/27/2014 Gary S. Jacob Chief Executive Officer 4,000 $4.18 $16,720.00
06/03/2014 John P. Brancaccio Director 3,500 $4.12 $14,420.00

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,804.71 -238.19 -1.40%
S&P 500 1,946.16 -26.13 -1.32%
NASDAQ 4,422.0850 -71.3050 -1.59%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs